Financial Information and Governance

Latest Financial Results


Revenue for the three and nine months ended September 30, 2023, was $7.3 million and $60.1 million, respectively, compared to $7.0 million and $16.1 million for the same periods in 2022.


As of September 30, 2023, Adaptimmune had cash and cash equivalents of $90.1 million and Total Liquidity1 of $161.7 million, compared to $108.0 million and $204.6 million, respectively, as of December 31, 2022.

1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

For complete information regarding our financials, see our periodic filings

Balance Sheet

Includes Current Assets, Liabilities and Stockholder's Equity

View Balance Sheet

Income Statement

Includes Total Net Sales, Cost & Expenses and Earnings per share

View Income Statement

Cash Flow

Includes Net Income, Adjustments, and Cash flows from investing & financing activities

View Cash Flow